Does the media refer more to CGTX or KMDA?

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.33 beat Kamada's score of 0.57 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGTX or FDMT?

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.33 beat 4D Molecular Therapeutics' score of 0.54 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NGNE or CGTX more profitable?

Neurogene's return on equity of -37.88% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Cognition Therapeutics N/A -72.68% -53.07%

Is FULC or CGTX more profitable?

Fulcrum Therapeutics' return on equity of -27.80% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -27.80% -26.32% Cognition Therapeutics N/A -72.68% -53.07%

Does the media favor FULC or CGTX?

In the previous week, Fulcrum Therapeutics had 20 more articles in the media than Cognition Therapeutics. MarketBeat recorded 24 mentions for Fulcrum Therapeutics and 4 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.33 beat Fulcrum Therapeutics' score of -0.58 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Negative Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADCT or CGTX?

In the previous week, ADC Therapeutics and ADC Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.33 beat ADC Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cognition Therapeutics (CGTX) Competitors

$1.40 -0.02 (-1.06%)

As of 02:30 PM Eastern

Compare

CGTX vs. KMDA, FDMT, NGNE, FULC, and ADCT

Should you buy Cognition Therapeutics stock or one of its competitors? MarketBeat compares Cognition Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cognition Therapeutics include Kamada (KMDA), 4D Molecular Therapeutics (FDMT), Neurogene (NGNE), Fulcrum Therapeutics (FULC), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.

How does Cognition Therapeutics compare to Kamada?

Cognition Therapeutics (NASDAQ:CGTX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Kamada has a net margin of 11.21% compared to Cognition Therapeutics' net margin of 0.00%. Kamada's return on equity of 7.73% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Kamada	11.21%	7.73%	5.41%

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 137.25%. Kamada has a consensus price target of $12.00, suggesting a potential upside of 62.60%. Given Cognition Therapeutics' higher probable upside, research analysts clearly believe Cognition Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Kamada has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.33 beat Kamada's score of 0.57 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Kamada	$180.46M	2.35	$20.20M	$0.35	21.09

Summary

Kamada beats Cognition Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cognition Therapeutics compare to 4D Molecular Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.33 beat 4D Molecular Therapeutics' score of 0.54 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cognition Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
4D Molecular Therapeutics	$85.21M	6.05	-$140.11M	-$2.57	N/A

Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, indicating that its stock price is 175% more volatile than the broader market.

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 137.25%. 4D Molecular Therapeutics has a consensus target price of $29.88, suggesting a potential upside of 202.84%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cognition Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Summary

4D Molecular Therapeutics beats Cognition Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cognition Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Cognition Therapeutics and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Cognition Therapeutics' score of 1.33 indicating that Neurogene is being referred to more favorably in the media.

Company	Overall Sentiment
Neurogene	Very Positive
Cognition Therapeutics	Positive

Cognition Therapeutics has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	464.32	-$90.35M	-$4.55	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Neurogene presently has a consensus target price of $73.13, indicating a potential upside of 167.56%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 137.25%. Given Neurogene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurogene is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Neurogene's return on equity of -37.88% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Neurogene has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Summary

Neurogene beats Cognition Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cognition Therapeutics has lower revenue, but higher earnings than Fulcrum Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	2.75	-$74.88M	-$1.15	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Fulcrum Therapeutics' return on equity of -27.80% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Cognition Therapeutics	N/A	-72.68%	-53.07%

In the previous week, Fulcrum Therapeutics had 20 more articles in the media than Cognition Therapeutics. MarketBeat recorded 24 mentions for Fulcrum Therapeutics and 4 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.33 beat Fulcrum Therapeutics' score of -0.58 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Negative
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulcrum Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 148.71%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 137.25%. Given Fulcrum Therapeutics' higher possible upside, research analysts clearly believe Fulcrum Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

Summary

Fulcrum Therapeutics beats Cognition Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, ADC Therapeutics and ADC Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.33 beat ADC Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cognition Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	2.17	-$142.62M	-$1.05	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

ADC Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

ADC Therapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 351.26%. Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 137.25%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cognition Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Summary

ADC Therapeutics beats Cognition Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$125.75M	$3.33B	$6.42B	$12.48B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-5.85	18.86	23.85	24.39
Price / Sales	N/A	319.25	520.29	116.29
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	3.60	6.82	10.04	6.74
Net Income	-$23.49M	$24.09M	$3.56B	$337.03M
7 Day Performance	18.07%	-2.69%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	356.76%	48.33%	28.56%	34.29%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	4.052 of 5 stars	$1.41 -1.1%	$3.33 +137.2%	+358.2%	$125.75M	N/A	N/A	20	Positive News Gap Down
KMDA Kamada	4.9358 of 5 stars	$7.83 +0.1%	$12.00 +53.3%	+9.8%	$450.26M	$180.46M	22.37	360
FDMT 4D Molecular Therapeutics	2.2774 of 5 stars	$8.60 -1.0%	$29.88 +247.4%	+146.3%	$449.57M	$88.24M	N/A	120	News Coverage
NGNE Neurogene	2.7573 of 5 stars	$27.71 +0.4%	$74.17 +167.7%	+27.5%	$437.87M	$930K	N/A	90	Analyst Forecast
FULC Fulcrum Therapeutics	2.148 of 5 stars	$6.57 -0.3%	$19.00 +189.2%	-54.2%	$437.78M	$80M	N/A	100	Trending News Analyst Downgrade Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. KMDA, FDMT, NGNE, FULC, and ADCT

How does Cognition Therapeutics compare to Kamada?

Summary

How does Cognition Therapeutics compare to 4D Molecular Therapeutics?

Summary

How does Cognition Therapeutics compare to Neurogene?

Summary

How does Cognition Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Cognition Therapeutics compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. KMDA, FDMT, NGNE, FULC, and ADCT

How does Cognition Therapeutics compare to Kamada?

Is CGTX or KMDA more profitable?

Do analysts prefer CGTX or KMDA?

Which has more volatility & risk, CGTX or KMDA?

Do insiders and institutionals hold more shares of CGTX or KMDA?

Does the media refer more to CGTX or KMDA?

Which has better earnings & valuation, CGTX or KMDA?

Summary

How does Cognition Therapeutics compare to 4D Molecular Therapeutics?

Does the media refer more to CGTX or FDMT?

Do insiders & institutionals hold more shares of CGTX or FDMT?

Which has higher earnings and valuation, CGTX or FDMT?

Which has more risk and volatility, CGTX or FDMT?

Do analysts prefer CGTX or FDMT?

Is CGTX or FDMT more profitable?

Summary

How does Cognition Therapeutics compare to Neurogene?

Do institutionals & insiders believe in NGNE or CGTX?

Does the media prefer NGNE or CGTX?

Which has better earnings and valuation, NGNE or CGTX?

Do analysts recommend NGNE or CGTX?

Is NGNE or CGTX more profitable?

Which has more volatility and risk, NGNE or CGTX?

Summary

How does Cognition Therapeutics compare to Fulcrum Therapeutics?

Do institutionals and insiders believe in FULC or CGTX?

Which has higher valuation and earnings, FULC or CGTX?

Is FULC or CGTX more profitable?

Does the media favor FULC or CGTX?

Do analysts recommend FULC or CGTX?

Which has more risk & volatility, FULC or CGTX?

Summary

How does Cognition Therapeutics compare to ADC Therapeutics?

Does the media favor ADCT or CGTX?

Do institutionals & insiders have more ownership in ADCT or CGTX?

Which has stronger valuation and earnings, ADCT or CGTX?

Which has more risk and volatility, ADCT or CGTX?

Do analysts recommend ADCT or CGTX?

Is ADCT or CGTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools